Merck win over Mylan related to Zetia, Vytorin patents upheld on appeal

theflyonthewall.com

The U.S. Court of Appeals for the Federal Circuit affirmed a lower court ruling in Merck's (MRK) favor in two jointly related patent infringement suits against Mylan Pharmaceuticals (MYL). The lower court previously found that Merck's patent which covers ezetimibe, an active ingredient in both Zetia and Vytorin, was valid and enforceable. The lower court also issued an injunction blocking the approval of Mylan's generic versions until the expiration of Merck's patent.

Rates

View Comments